Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 430 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Emesis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

NCT00404378
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ketoconazole, casopitant 100 mg, Casopitant 50 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

NCT01596400
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
granisetron transdermal system, Granisetron IV
Drug
Lead sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Industry
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Not applicable Interventional

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Nausea and Vomiting, Pain
Interventions
questionnaire administration, hypnotherapy, therapeutic conventional surgery
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 25, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

NCT05065567
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
Droperidol, Haloperidol, Ondansetron 8mg
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?

NCT03338400
View directory record Official record
Conditions
Quality of Recovery, Same Day Surgery, Nausea and Vomiting, Postoperative, Vaginal Prolapse
Interventions
Dexamethasone, Normal saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion

NCT05759481
View directory record Official record
Conditions
Post-operative Nausea and Vomiting
Interventions
Hybrid anesthesia (propofol + sevoflurane), Propofol only TIVA
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Not listed Not applicable Interventional

Medtronic Enterra II Neurostimulator

NCT06215547
View directory record Official record
Conditions
Gastroparesis
Interventions
Enterra HDE
Device
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 25, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Oral Hydration in the Ambulatory Arthroplasty Population

NCT05520593
View directory record Official record
Conditions
Same-day Discharge, Length of Stay
Interventions
Complex Carbohydrate Drink
Dietary Supplement
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean

NCT02959840
View directory record Official record
Conditions
Nausea, Vomiting, Satisfaction
Interventions
Acupressure Point P6 stimulator, Metoclopramide, Ondansetron
Device · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 25, 2026, 5:04 PM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01376297
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
11
States / cities
Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting

NCT00250744
View directory record Official record
Conditions
Cancer
Interventions
Aprepitant vs. Gabapentin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

NCT01586806
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction, Regional Anesthesia, Saphenous Nerve Block
Interventions
Bupivacaine Only, Bupivacaine with 1 mg of Dexamethasone, Bupivacaine with 4 mg of Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
16 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

NCT03657810
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 5 mg, Norco, Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Auricular Neurostimulation for Cyclic Vomiting Syndrome

NCT03434652
View directory record Official record
Conditions
Cyclic Vomiting Syndrome, Abdominal Migraine
Interventions
Percutaneous neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
8 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

NCT01346267
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Real Acupressure Band, Placebo Acupressure Band
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
4 Years to 18 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
24
States / cities
Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

NCT00967499
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Hills, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

SAFEstart Feeding Intolerance Study Phase II

NCT00331201
View directory record Official record
Conditions
Feeding Intolerance, Abdominal Distention, Gastric Residual, Emesis and Diarrhea, Blood in Stool
Interventions
SAFEstart
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Oct 25, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Autonomic Reactivity and Personalized Neurostimulation

NCT06863207
View directory record Official record
Conditions
Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome, Functional Dyspepsia, Dysautonomia
Interventions
Percutaneous electrical nerve field stimulation, Hypnotherapy
Device · Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

NCT05676294
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Brain-Stomach Circuits in Chronic Nausea

NCT07276035
View directory record Official record
Conditions
Chronic Nausea and Vomiting Syndrome
Interventions
Transcranial Magnetic Stimulation, TMS
Device
Lead sponsor
David Levinthal
Other
Eligibility
21 Years to 60 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 25, 2026, 5:04 PM EDT